Could the AIIMS-led Trial of the Most Advanced Brain Stent Revolutionize Stroke Treatment?
Synopsis
The groundbreaking Supernova Stent, developed by Gravity Medical Technology, has shown remarkable promise in treating stroke patients. With its recent approval in India, this innovative device aims to transform stroke care and provide new hope to millions. Could this be a game-changer for the future of stroke treatment?
Key Takeaways
Innovative Treatment: The Supernova Stent represents a major advancement in stroke care.
Proven Results: Clinical trials show excellent safety and efficacy.
Domestic Production: The device will be manufactured in India at affordable prices.
Impact on Lives: Offers hope to the 1.7 million stroke patients in India.
Global Standpoint: Positions India as a leader in advanced medical technology.
New Delhi, Dec 13 (NationPress) The Supernova Stent — an innovative brain treatment device — has been proven to be both safe and effective for stroke patients, as reported by specialists at AIIMS Delhi, who spearheaded the inaugural clinical trial.
AIIMS Delhi served as the national coordinating center and the primary enrolling site for the GRASSROOT trial involving the Supernova Stent.
“This trial marks a pivotal moment for stroke treatment in India,” stated Dr. Shailesh B. Gaikwad, Professor and Head of the Department of Neuroimaging & Interventional Neuroradiology at AIIMS Delhi, and National Principal Investigator of the GRASSROOT Trial.
“According to preliminary trial results, the Supernova stent has exhibited outstanding safety and efficacy outcomes in the management of severe strokes,” he elaborated, referencing findings published in the esteemed Journal of Neurointerventional Surgery (JNIS).
In the initial prospective multicenter thrombectomy trial, the Supernova stent retriever achieved a high rate of successful blood flow restoration, with a brain bleed rate of just 3.1 percent, a mortality rate of 9.4 percent, and 50 percent functional independence at 90 days.
Developed by Gravity Medical Technology, the Supernova is tailored for India's diverse patient demographics, where strokes frequently affect younger individuals compared to Western countries.
Earlier this year, data from the GRASSROOT trial received approval from the Central Drugs Standard Control Organisation (CDSCO), allowing the Supernova stent-retriever to be utilized routinely in India.
The GRASSROOT India trial, which verified the device's safety and efficacy in addressing life-threatening strokes, was conducted across eight centers. Experts note that this trial represents a significant achievement for the Make-in-India initiative, establishing India as a key player in advanced stroke care.
“The device has already treated over 300 patients in Southeast Asia and will soon be manufactured domestically, making it available in India at affordable prices, thereby providing new hope to the 1.7 million Indians affected by strokes annually,” said Dr. Dileep Yavagal, Professor of Neurology and Neurosurgery at the University of Miami, involved in the global trial.
Point of View
It is crucial to highlight how the advancements in stroke treatments, like the Supernova Stent, align with India's healthcare goals. This innovative solution not only enhances our medical capabilities but also signifies a shift towards self-reliance in medical technology, reinforcing our commitment to improving the health of our citizens.
NationPress
9 May 2026
Frequently Asked Questions
What is the Supernova Stent?
The Supernova Stent is an advanced brain treatment device specifically designed to treat severe strokes, demonstrating both safety and effectiveness.
Who conducted the GRASSROOT trial?
The GRASSROOT trial was led by AIIMS Delhi, which served as the national coordinating center and primary enrolling site.
What were the key findings from the trial?
The trial found that the Supernova stent achieved high rates of blood flow restoration, with low brain bleed and mortality rates, and significant functional independence at 90 days.
Is the Supernova Stent approved for use in India?
Yes, the Central Drugs Standard Control Organisation (CDSCO) has approved the Supernova stent-retriever for routine use in India.
How many patients have been treated with the Supernova Stent?
The device has successfully treated over 300 patients in Southeast Asia and is now set to be manufactured and made available in India.
